Tag: FDA-approved immunotherapy 2024

Home / FDA-approved immunotherapy 2024

Categories

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer

Nogapendekin alfa inbakicept-pmln with BCG for bladder cancer There is a type of bladder cancer called NMIBC that does not spread to the muscles. The Food and Drug Administration has approved the use...
fda-approved-immunotherapy-2024

Scan the code